Investor Information

Press Releases

Express Scripts Announces 3rd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point

ST. LOUIS, Oct. 28, 2014 /PRNewswire/ -- Express Scripts Holding Company (Nasdaq: ESRX) announced 2014 third quarter net income attributable to Express Scripts stockholders of $582.3 million, or $0.78 per diluted share. Adjusted earnings per diluted share, as detailed in Table 4, was $1.29 for the third quarter.1  

"We have continually improved the pharmacy benefit over nearly three decades, and we're positioning ourselves to drive further advances," stated George Paz, chairman and chief executive officer.  "The pharmacy benefit is the most used benefit by members and represents the biggest opportunity to add value to healthcare by making it easier to access, more affordable, safer, and more effective.  Looking forward, we are allocating the necessary resources to develop innovative solutions aimed at controlling costs and providing a patient-centric model that delivers best in class services to our clients and their members."

Third Quarter 2014 Review  

The expected roll-off of UnitedHealth Group ("UNH") claims was completed by the end of 2013.  The following table compares the third quarter 2014 and 2013 operating results from continuing operations excluding and including UNH (also see Tables 7 and 8):

(from continuing operations)

Q3 2014

(in millions, except per share and per claim data)

Q3 2014 Change

From Q3 2013

Excluding UNH

Including UNH

Total adjusted claims (see Table 1)

328.3

(4%)

(8%)

Adjusted EBITDA (see Table 3)

$       1,739.2

8%

5%

Adjusted EBITDA, per adjusted claim (see Table 3)

$            5.30

13%

14%

GAAP net income

$          582.3

42%

32%

Adjusted net income (see Table 5)

$          962.5

12%

8%

GAAP diluted earnings per share

$            0.78

56%

44%

Adjusted earnings per diluted share (see Table 4)

$            1.29

24%

19%

Third quarter net cash flow provided by operating activities was $435.1 million and the Company repurchased 14.1 million shares of common stock for $1,013.6 million during the quarter, leaving 28.8 million shares available under the current repurchase program.       

2014 Guidance

The Company narrowed its adjusted earnings per diluted share guidance from a range of $4.84 to $4.92 to a range of $4.86 to $4.90, which maintains the mid-point of $4.88.  The new guidance range reflects year over year growth of 18% to 19% excluding UNH (see Table 8) or growth of 12% to 13% including UNH. 

As a result of certain tax planning strategies, the adjusted effective income tax rate guidance improved from a range of 38.0% to 38.2% to a range of 37.6% to 37.8%.  Additional details on this guidance and items excluded from this range can be found in Table 6.

The Company expects the following for the fourth quarter of 2014 – (see Table 6):

(from continuing operations)

Estimated Quarter Ending December 31, 2014

(in millions, except per share data)

Year Over Year Growth

(Excluding UNH)

Year Over Year Growth (Including UNH)

Adjusted claims

317 to 337

(10%) – (4%)

(12%) – (7%)

Adjusted earnings per diluted share

$1.36 to $1.40

24% - 27%

21% - 25%

About Express Scripts

Express Scripts manages more than a billion prescriptions each year for tens of millions of patients. On behalf of our clients – employers, health plans, unions and government health programs – we make the use of prescription drugs safer and more affordable. Express Scripts uniquely combines three capabilities – behavioral sciences, clinical specialization and actionable data – to create Health Decision Science℠, our innovative approach to help individuals make the best drug choices, pharmacy choices and health choices. Better decisions mean healthier outcomes.

Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery, specialty benefit management, benefit-design consultation, drug-utilization review, formulary management, and medical and drug data analysis services. The company also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.

For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.

SAFE HARBOR STATEMENT

This press release contains forward-looking statements, including, but not limited to, our 2014 guidance and our statements related to the Company's plans, objectives, expectations (financial and otherwise) or intentions. Actual results may differ significantly from those projected or suggested in any forward-looking statements.  Factors that may impact these forward-looking statements can be found in the Management's Discussion and Analysis of Financial Condition and Results of Operations section of the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission ("SEC") on October 28, 2014 and Item 1A – "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on February 20, 2014.  A copy of these documents can be found at the Investor Information section of Express Scripts' web site at http://www.express-scripts.com/corporate.

We do not undertake any obligation to release publicly any revisions to such forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

1 All net income, earnings per share, adjusted EBITDA, adjusted EBITDA per adjusted claims, adjusted net income and adjusted earnings per share amounts are presented as attributable to Express Scripts, excluding non-controlling interest representing the share allocated to members of our consolidated affiliates.   


 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Operations 










Three Months Ended
September 30,


Nine Months Ended
September 30,

  (in millions, except per share data) 

2014


2013


2014


2013









Revenues(*)

$ 25,778.5


$ 25,915.6


$ 74,574.5


$ 78,317.4

Cost of revenues(*)

23,705.5


23,921.4


68,743.4


72,246.0

    Gross profit 

2,073.0


1,994.2


5,831.1


6,071.4

Selling, general and administrative

1,088.6


1,118.7


3,171.5


3,348.5

Operating income

984.4


875.5


2,659.6


2,722.9

Other (expense) income:








    Equity income from joint venture 

7.2


6.3


13.6


23.1

    Interest income  

8.3


25.7


23.3


28.4

    Interest expense and other 

(201.6)


(127.4)


(460.8)


(470.4)


(186.1)


(95.4)


(423.9)


(418.9)

Income before income taxes

798.3


780.1


2,235.7


2,304.0

Provision for income taxes

209.2


326.5


789.4


896.0

Net income from continuing operations

589.1


453.6


1,446.3


1,408.0

Net loss from discontinued operations, net of tax

-


(15.5)


-


(41.3)

Net income

589.1


438.1


1,446.3


1,366.7

Less: Net income attributable to non-controlling interest

6.8


11.4


20.5


24.0

Net income attributable to Express Scripts

$      582.3


$      426.7


$   1,425.8


$   1,342.7









Weighted-average number of common shares








 outstanding during the period: 








    Basic 

738.1


810.2


757.1


814.7

    Diluted 

746.0


822.9


766.1


828.0









Basic earnings per share:








     Continuing operations attributable to Express Scripts

$        0.79


$        0.55


$        1.88


$        1.70

     Discontinued operations attributable to Express Scripts

-


(0.02)


-


(0.05)

     Net earnings attributable to Express Scripts

0.79


0.53


1.88


1.65









Diluted earnings per share:








     Continuing operations attributable to Express Scripts

$        0.78


$        0.54


$        1.86


$        1.67

     Discontinued operations attributable to Express Scripts

-


(0.02)


-


(0.05)

     Net earnings attributable to Express Scripts

0.78


0.52


1.86


1.62









Amounts attributable to Express Scripts shareholders:








     Income from continuing operations, net of tax

$      582.3


$      442.2


$   1,425.8


$   1,384.0

     Discontinued operations, net of tax

-


(15.5)


-


(41.3)

     Net income attributable to Express Scripts shareholders

$      582.3


$      426.7


$   1,425.8


$   1,342.7









(*) Includes retail pharmacy co-payments of $2,418.3 million and $2,966.5 million for the three months ended September 30, 2014 and 2013, respectively, and $7,894.7 million and $9,845.2 million for the nine months ended September 30, 2014 and 2013, respectively.

 

 

 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Balance Sheet 






 September 30,


 December 31,

 (in millions) 

2014


2013

 Assets 




 Current assets: 




 Cash and cash equivalents 

$               834.8


$           1,991.4

 Restricted cash and investments 

23.5


22.8

 Receivables, net 

6,384.5


4,022.9

 Inventories 

1,789.8


1,871.1

 Deferred taxes 

439.5


455.4

 Prepaid expenses and other current assets 

232.6


96.8

 Current assets of discontinued operations 

-


31.0

    Total current assets 

9,704.7


8,491.4

 Property and equipment, net 

1,639.9


1,658.9

 Goodwill 

29,304.3


29,305.4

 Other intangible assets, net 

12,695.6


14,015.6

 Other assets 

94.7


76.9

    Total assets 

$          53,439.2


$         53,548.2





 Liabilities and stockholders' equity 




 Current liabilities: 




 Claims and rebates payable 

$            7,815.0


$           6,767.8

 Accounts payable 

2,971.5


2,900.0

 Accrued expenses 

1,890.6


1,982.2

 Current maturities of long-term debt 

3,245.4


1,584.0

 Current liabilities of discontinued operations 

-


1.3

    Total current liabilities 

15,922.5


13,235.3

 Long-term debt 

11,442.0


12,363.0

 Deferred taxes 

5,209.5


5,440.6

 Other liabilities 

696.9


664.4

 Noncurrent liabilities of discontinued operations 

-


0.1

    Total liabilities 

33,270.9


31,703.4





 Stockholders' equity: 




 Preferred stock, 15.0 shares authorized, $0.01 par value per share; and no shares issued and outstanding 

-


-

 Common stock, 2,985.0 shares authorized, $0.01 par value per share; shares issued: 846.3 and 834.0, respectively; shares outstanding: 733.9 and 773.6, respectively 

8.5


8.3

 Additional paid-in capital 

22,532.3


21,809.9

 Accumulated other comprehensive income 

7.0


11.7

 Retained earnings 

5,338.6


3,912.8


27,886.4


25,742.7





 Common stock in treasury at cost, 112.4 and 60.4 shares, respectively 

(7,728.7)


(3,905.3)

    Total Express Scripts stockholders' equity 

20,157.7


21,837.4

 Non-controlling interest 

10.6


7.4

    Total stockholders' equity 

20,168.3


21,844.8

    Total liabilities and stockholders' equity 

$          53,439.2


$         53,548.2

 

 

 EXPRESS SCRIPTS HOLDING COMPANY 

 Unaudited Consolidated Statement of Cash Flows 


 Nine Months Ended
September 30,

 (in millions) 

2014


2013





 Cash flows from operating activities: 




 Net income 

$ 1,446.3


$ 1,366.7

 Net loss from discontinued operations, net of tax 

-


41.3

      Net income from continuing operations 

1,446.3


1,408.0

 Adjustments to reconcile net income to net cash provided by operating activities: 




 Depreciation and amortization 

1,658.2


1,824.0

 Deferred income taxes 

(272.9)


(376.2)

 Employee stock-based compensation expense 

82.3


131.2

 Other, net 

(17.1)


25.8

 Changes in operating assets and liabilities:  




 Accounts receivable 

(2,420.3)


194.5

 Inventories 

81.3


8.6

 Other current and noncurrent assets 

(146.3)


37.3

 Claims and rebates payable 

1,047.2


(980.3)

 Accounts payable 

93.1


(320.5)

 Other current and noncurrent liabilities 

72.8


(109.3)

 Net cash provided by operating activities - continuing operations 

1,624.6


1,843.1

 Net cash used in operating activities - discontinued operations 

-


(20.7)

 Net cash flows provided by operating activities 

1,624.6


1,822.4





 Cash flows from investing activities: 




 Purchases of property and equipment 

(327.0)


(274.6)

 Proceeds from sale of business 

-


313.0

 Other 

7.7


(26.3)

 Net cash (used in) provided by investing activities - continuing operations 

(319.3)


12.1

 Net cash used in investing activities - discontinued operations 

-


(2.1)

 Net cash (used in) provided by investing activities 

(319.3)


10.0





 Cash flows from financing activities: 




 Treasury stock acquired 

(3,673.5)


(1,552.5)

 Proceeds from long-term debt, net of discounts 

2,490.1


-

 Repayment of long-term debt 

(1,723.7)


(1,773.7)

 Net proceeds from employee stock plans 

419.4


383.6

 Excess tax benefit relating to employee stock compensation 

75.4


23.2

 Distributions paid to non-controlling interest 

(17.1)


(18.0)

 Other 

(29.1)


15.4

 Net cash used in financing activities 

(2,458.5)


(2,922.0)





 Effect of foreign currency translation adjustment 

(3.4)


(4.5)





 Less: cash decrease attributable to discontinued operations 

-


23.3





 Net decrease in cash and cash equivalents 

(1,156.6)


(1,070.8)

 Cash and cash equivalents at beginning of period 

1,991.4


2,793.1

 Cash and cash equivalents at end of period 

$    834.8


$ 1,722.3

 

 


 Table 1 

  Express Scripts Holding Company Unaudited Consolidated Selected Information 

 (in millions) 










 Three Months Ended
September 30,


 Nine Months Ended
September 30,


2014


2013


2014


2013

Claims Volume








Continuing operations:








Network

231.3


256.9


693.0


805.9

Home delivery and specialty(1)

33.1


34.6


95.6


106.6

   Total claims 

264.4


291.5


788.6


912.5









Total adjusted claims - continuing operations(2)

328.3


358.1


972.8


1,117.3









 Depreciation and Amortization (D&A):  








 Revenue amortization(3)

$   28.5


$   28.5


$      85.5


$      85.5

 Cost of revenues depreciation 

33.2


31.4


95.9


88.7

 Selling, general and administrative depreciation 

72.1


77.3


244.7


222.7

 Selling, general and administrative amortization(3)

413.2


477.1


1,232.1


1,427.1

      Total D&A - continuing operations 

$ 547.0


$ 614.3


$ 1,658.2


$ 1,824.0









 Generic Fill Rate* 








 Network 

84.0%


81.6%


83.7%


81.6%

 Home delivery 

77.5%


74.8%


76.9%


74.5%

 Overall 

83.1%


80.8%


82.9%


80.7%









 Note: See Appendix for Footnotes 









*The home delivery generic fill rate is currently lower than the network generic fill rate as fewer generic substitutions are available among maintenance medications (e.g. therapies for chronic conditions) commonly dispensed from home delivery pharmacies compared to acute medications which are primarily dispensed by pharmacies in our retail networks.

 

 


Table 2

Calculation of Express Scripts Holding Company Adjusted Gross Profit and SG&A - Continuing Operations

(in millions)










 Three Months Ended
September 30,


 Nine Months Ended
September 30,


2014


2013


2014


2013

Gross profit, as reported

$ 2,073.0


$ 1,994.2


$ 5,831.1


$ 6,071.4

Amortization of intangible assets (3)

28.5


28.5


85.5


85.5

Transaction and integration costs (4)

65.0


56.8


281.4


137.9

Adjusted gross profit

$ 2,166.5


$ 2,079.5


$ 6,198.0


$ 6,294.8









Selling, general and administrative, as reported

$ 1,088.6


$ 1,118.7


$ 3,171.5


$ 3,348.5

Amortization of intangible assets (3)

413.2


477.1


1,232.1


1,427.1

Transaction and integration costs (4)

157.7


130.8


412.8


346.2

Adjusted selling, general and administrative

$    517.7


$    510.8


$ 1,526.6


$ 1,575.2


 Note: See Appendix for Footnotes 









The Company is providing adjusted gross profit and adjusted selling, general and administrative expenses (both of which are non-GAAP financial measures), in each case, excluding the impact of amortization of intangible assets and transaction and integration costs in order to compare the underlying financial performance to prior periods.

 

 

 Table 3 

 Express Scripts Holding Company EBITDA Reconciliation 

 (in millions, except per claim data) 

The following is a reconciliation of net income from continuing operations attributable to Express Scripts to EBITDA from continuing operations attributable to Express Scripts.  The Company believes net income is the most directly comparable measure calculated under U.S. GAAP.  



 Three Months Ended
September 30,


 Nine Months Ended
September 30,


2014


2013


2014


2013

Net income from continuing operations, attributable to Express Scripts, as reported

$    582.3


$    442.2


$ 1,425.8


$ 1,384.0

  Provision for income taxes

209.2


326.5


789.4


896.0

  Depreciation and amortization*

547.0


614.3


1,658.2


1,824.0

  Interest expense, net

193.3


101.7


437.5


442.0

  Equity income from joint venture

(7.2)


(6.3)


(13.6)


(23.1)

EBITDA from continuing operations, attributable to Express Scripts, as reported

1,524.6


1,478.4


4,297.3


4,522.9

Transaction and integration costs (4)*

214.6


178.5


648.1


473.0

Adjusted EBITDA from continuing operations, attributable to Express Scripts

$ 1,739.2


$ 1,656.9


$ 4,945.4


$ 4,995.9









Total adjusted claims - continuing operations

328.3


358.1


972.8


1,117.3









Adjusted EBITDA from continuing operations, attributable to Express Scripts, per adjusted claim

$      5.30


$      4.63


$      5.08


$      4.47










 Note: See Appendix for Footnotes 


















 The Company is providing EBITDA and adjusted EBITDA excluding the impact of certain charges (both of which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods. 










EBITDA from continuing operations is earnings before other income (expense), interest, taxes, depreciation and amortization, or alternatively calculated as operating income from continuing operations plus depreciation and amortization less non-controlling interest.  EBITDA from continuing operations is presented because it is a widely accepted indicator of a company's ability to service indebtedness and is frequently used to evaluate a company's performance.  EBITDA from continuing operations, however, should not be considered as an alternative to net income from continuing operations, as a measure of operating performance, as an alternative to cash flow, as a measure of liquidity or as a substitute for any other measure computed in accordance with accounting principles generally accepted in the United States.  In addition, our definition and calculation of EBITDA from continuing operations may not be comparable to that used by other companies.










Adjusted EBITDA from continuing operations per adjusted claim is a supplemental measurement used by analysts and investors to help evaluate overall operating performance.  We have calculated adjusted EBITDA from continuing operations excluding transaction and integration costs recorded each year, as these charges are not considered an indicator of ongoing company performance.  Adjusted EBITDA from continuing operations per adjusted claim is calculated by dividing adjusted EBITDA from continuing operations by the adjusted claim volume for the period.  This measure is used as an indicator of EBITDA performance on a per-unit basis.  Adjusted EBITDA from continuing operations, and as a result, adjusted EBITDA from continuing operations per adjusted claim, are each affected by the changes in claim volumes between retail and home delivery, the relative representation of brand-name, generic and specialty pharmacy drugs, as well as the level of efficiency in the business.


*  Depreciation and amortization for the three and nine months ended September 30, 2014 presented above includes $8.1 million and $46.1 million, respectively, of depreciation related to the integration of Medco which is not included in transaction and integration costs.  Depreciation and amortization for the three and nine months ended Septmber 30, 2013 presented above includes $9.1 million and $11.1 million, respectively, of depreciation related to the integration of Medco which is not included in transaction and integration costs.  

 

 

 Table 4 

 Calculation of Express Scripts Holding Company Adjusted Diluted EPS  










 Three Months Ended
September 30,


 Nine Months Ended
September 30,


2014


2013


2014


2013




(per diluted share)



EPS from continuing operations attributable to Express Scripts, as reported

$ 0.78


$ 0.54


$ 1.86


$ 1.67









Excluding items indicated: 








Transaction and integration costs (4)

0.19


0.14


0.57


0.36

Debt redemption costs (5)

0.06


-


0.06


0.05

Discrete tax items (6)

(0.11)


0.05


(0.06)


0.04

Interest payment(7)

-


(0.02)


-


(0.02)

Amortization of intangible assets (3)

0.37


0.37


1.07


1.11









EPS from continuing operations attributable to Express Scripts, adjusted

$ 1.29


$ 1.08


$ 3.50


$ 3.21

















 Note: See Appendix for Footnotes 









The Company is providing diluted EPS from continuing operations attributable to Express Scripts and adjusted diluted EPS from continuing operations attributable to Express Scripts excluding the impact of transaction, integration and certain other costs and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

 

 


 Table 5 

 Calculation of Express Scripts Holding Company Adjusted Net Income and Adjusted Effective Income Tax Rate 

 (in millions) 


 Three Months Ended
September 30, 2014


 Nine Months Ended
September 30, 2014


Income before income taxes


Provision for income taxes


Effective income tax rate


Income before income taxes


Provision for income taxes


Effective income tax rate

Income, as reported

$    798.3


$     209.2




$ 2,235.7


$     789.4



Non-controlling interest

(6.8)


-




(20.5)


-



Total attributable to Express Scripts, as reported

791.5


209.2


26.4%


2,215.2


789.4


35.6%













Excluding items indicated: 












Transaction and integration costs(4)

222.7


82.1




694.2


261.6



Debt redemption costs(5)

71.5


26.9




75.9


28.6



Discrete tax items(6)



83.6






45.6



Amortization of intangible assets(3)

441.7


163.1




1,317.6


496.6















Total attributable to Express Scripts, as adjusted

$ 1,527.4


$     564.9


37.0%


$ 4,302.9


$  1,621.8


37.7%













Adjusted net income attributable to Express












    Scripts, net of tax



$     962.5






$  2,681.1















 Note: See Appendix for Footnotes. 













The Company is providing adjusted net income attributable to Express Scripts, net of tax and adjusted effective income tax rate attributable to Express Scripts excluding the impact of certain items and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

 

 


 Table 5A 

 Calculation of Express Scripts Holding Company Adjusted Net Income and Adjusted Effective Income Tax Rate for Continuing Operations 

 (in millions) 


 Three Months Ended
September 30, 2013


 Nine Months Ended
September 30, 2013


Income before income taxes


Provision for income taxes


Effective income tax rate


Income before income taxes


Provision for income taxes


Effective income tax rate

Income from continuing operations, as reported

$    780.1


$     326.5




$ 2,304.0


$     896.0



Non-controlling interest

(11.4)


-




(24.0)


-



Total continuing  operations attributable to Express Scripts, as reported

768.7


326.5


42.5%


2,280.0


896.0


39.3%













Excluding items indicated: 












Transaction and integration costs(4)

187.6


72.2




484.1


188.8



Debt redemption costs(5)

-


-




68.5


26.9



Discrete tax items(6)

-


(38.7)




-


(29.7)



Interest payment (7)

(24.9)


(9.7)




(24.9)


(9.7)



Amortization of intangible assets(3)

505.6


194.3




1,512.6


590.1















Total continuing operations attributable to Express Scripts, as adjusted

$ 1,437.0


$     544.6


37.9%


$ 4,320.3


$  1,662.4


38.5%













Adjusted net income from continuing operations attributable to Express












    Scripts, net of tax



$     892.4






$  2,657.9















 Note: See Appendix for Footnotes. 













The Company is providing adjusted net income from continuing operations attributable to Express Scripts, net of tax and adjusted effective income tax rate from continuing operations attributable to Express Scripts excluding the impact of certain items and amortization of intangible assets (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.

 

 


 Table 6 

 Express Scripts Holding Company 2014 Guidance Information 



Estimated Year Ending December 31, 2014


Estimated Year Ending December 31, 2014

  (in millions, except per share and per claim data) 

 Current Guidance 


 Previous Guidance 





Adjusted earnings per diluted share attributable to Express Scripts*

$4.86 to $4.90


$4.84 to $4.92

Year over year growth excluding UNH - See Table 8

18%-19%


17%-19%





Total adjusted claims

1,290 to 1,310


1,275 to 1,325





Adjusted selling, general and administrative*

$2,025 to $2,100


$1,950 to $2,025





Depreciation**

$400 to $420


$400 to $420





Effective income tax rate 

37.6% to 37.8%


38.0% to 38.2%





Adjusted EBITDA*

$6,750 to $6,850


$6,775 to $6,925





Adjusted EBITDA per adjusted claim*

$5.20 to $5.30


$5.20 to $5.30





Diluted weighted average shares outstanding during the period

750 to 760


750 to 760





Cash flow from operations

$4,550 to $5,150


$4,550 to $5,150





Capital expenditures

$400 to $450


$400 to $450





GAAP items not included in guidance (*) 

The full-year impact of integration and certain other costs has yet to be determined.  Accordingly, the Company is unable to include these charges in the list of GAAP items not included in guidance for 2014 full-year and third quarter adjusted EPS, adjusted selling, general and administrative, adjusted EBITDA and adjusted EBITDA per adjusted claim or to provide a reconciliation to the corresponding GAAP measure.  These integration expenses are expected to end in the fourth quarter of 2014.  2014 Adjusted EPS will exclude amortization of intangible assets per diluted share in the range of $1.43 to $1.47.





**  Approximately $280 to $300 million of this depreciation guidance is included in the guidance for adjusted selling, general and administrative expenses.  The remainder of the depreciation guidance is reported in costs of goods sold.

 

 


 Table 7 

 Express Scripts Holding Company Operating Results Excluding UnitedHealth Group ("UNH") 

(Amounts in millions except per share and per claim data)







Q3 2013










UNH

Excluding


Q3 2014 Change

(Three Months Ended)


Q3 2014


Q3 2013

(Table 8)

UNH


Including UNH

Excluding UNH












Adjusted claims

Table 1

328.3


358.1

(15.8)

342.3


-8%


-4%












Adjusted SG&A

Table 2

$    517.7


$    510.8

$    (2.5)

$    508.3


1%


2%












Adjusted EBITDA

Table 3

$ 1,739.2


$ 1,656.9

$  (53.0)

$ 1,603.9


5%


8%












Adjusted EBITDA, per adjusted claim

Table 3

$      5.30


$      4.63

$    3.36

$      4.69


14%


13%












GAAP net income


$    582.3


$    442.2

$  (32.9)

$    409.3


32%


42%












Adjusted net income

Table 5

$    962.5


$    892.4

$  (32.9)

$    859.5


8%


12%












GAAP diluted earnings per share


$      0.78


$      0.54

$  (0.04)

$      0.50


44%


56%












Adjusted diluted earnings per share

Table 4

$      1.29


$      1.08

$  (0.04)

$      1.04


19%


24%


















Q3 2013










UNH

Excluding


Q3 2014 Change

(Nine Months Ended)


Q3 2014


Q3 2013

(Table 8)

UNH


Including UNH

Excluding UNH












Adjusted claims

Table 1

972.8


1,117.3

(81.2)

1,036.1


-13%


-6%












Adjusted SG&A

Table 2

$ 1,526.6


$ 1,575.2

$    (7.4)

$ 1,567.8


-3%


-3%












Adjusted EBITDA

Table 3

$ 4,945.4


$ 4,995.9

$(233.7)

$ 4,762.2


-1%


4%












Adjusted EBITDA, per adjusted claim

Table 3

$      5.08


$      4.47

$    2.88

$      4.60


14%


10%












GAAP net income


$ 1,425.8


$ 1,384.0

$(143.5)

$ 1,240.5


3%


15%












Adjusted net income

Table 5

$ 2,681.1


$ 2,657.9

$(143.5)

$ 2,514.4


1%


7%












GAAP diluted earnings per share


$      1.86


$      1.67

$  (0.17)

$      1.50


11%


24%












Adjusted diluted earnings per share

Table 4

$      3.50


$      3.21

$  (0.17)

$      3.04


9%


15%












The Company is providing operating results excluding UNH (which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.












Amounts presented as continuing operations.  

 

 



 Table 8 

 Express Scripts Holding Company - UnitedHealth Group ("UNH")  Contribution by Quarter 

(Amounts in millions except per share and per claim data)
















Full Year



Q1 2013

Q2 2013

Q3 2013

Q4 2013


2013









Adjusted claims


37

28

16

8


89









Adjusted SG&A


$          2

$        2

$           2

$          2


$              10









Adjusted EBITDA


$        94

$      87

$         53

$        29


$            263









Adjusted EBITDA, per adjusted claim

$     2.51

$   3.10

$      3.36

$     3.52


$           2.94









Adjusted net income


$        57

$      54

$         33

$        18


$            162









Adjusted diluted earnings per share

$     0.07

$   0.06

$      0.04

$     0.02


$           0.20

















Adjusted diluted earnings per share







as reported:


$     0.99

$   1.13

$      1.08

$     1.12


$           4.33









Adjusted diluted earnings per share







excluding UNH:


$     0.92

$   1.07

$      1.04

$     1.10


$           4.13









The Company is providing UNH 2013 operating results by quarter and adjusted diluted earnings per share excluding UNH (both of which are non-GAAP financial measures) in order to compare the underlying financial performance to prior periods.









Amounts presented as continuing operations. 

 

 

 Appendix 

 Footnotes 


(1)Includes home delivery, specialty and other including:  (a) drugs distributed through patient assistance programs (b) drugs we distribute to clients of other PBMs under limited distribution contracts with pharmaceutical manufacturers and (c) FreedomFP claims. 


(2) Total adjusted claims reflect home delivery claims multiplied by 3, as home delivery claims typically cover a time period 3 times longer than network claims. 


(3)Amortization of intangible assets includes the following items:

 

Amortization of legacy Express Scripts intangible assets include amounts in both revenues and selling, general and administrative expense.

 

Revenue amortization is related to the customer contract with WellPoint (now known as Anthem) which commenced upon closing of the NextRx acquisition in 2009.  Under U.S. GAAP, amortization of intangibles that arise in connection with consideration given to a customer by a vendor is characterized as a reduction of revenues.  Intangible amortization of $28.5 million ($18.0 million and $17.5 million net of tax in 2014 and 2013, respectively) is included as a reduction to revenue for the three months ended September 30, 2014 and 2013.  Intangible amortization of $85.5 million ($53.3 million and $52.1 million net of tax in 2014 and 2013, respectively) is included as a reduction to revenue for the nine months ended September 30, 2014 and 2013.


Other legacy Express Scripts intangible amortization of $9.5 million ($5.9 million net of tax) and $10.2 million ($6.3 million net of tax) for the three months ended September 30, 2014 and 2013, respectively, is included in selling, general and administrative expense.   Other legacy Express Scripts intangible amortization of $28.3 million ($17.6 million net of tax) and $30.5 million ($18.6 million net of tax) for the nine months ended September 30, 2014 and 2013, respectively, is included in selling, general and administrative expense.


Amortization of intangible assets related to the acquisition of Medco Health Solutions, Inc. ("Medco") of $403.7million ($254.7 million net of tax) and $466.9 million ($287.5 million net of tax) for the three months ended September 30, 2014  and 2013, respectively, is included in selling, general and administrative expense.  Amortization of intangible assets related to the acquisition of Medco of $1,203.8 million ($750.1 million net of tax) and $1,396.6 million ($851.8 million net of tax) for the nine months ended September 30, 2014  and 2013, respectively, is included in selling, general and administrative expense.


(4)Transaction and integration costs include those costs directly related to the acquisition of Medco. 


Costs of $65.0 million ($41.4 million net of tax) and $56.8 million ($34.9 million net of tax) primarily composed of integration-related activities, are included in gross profit for the three months ended September 30, 2014 and 2013, respectively.  Costs of $281.4 million ($175.4 million net of tax) and $137.9 million ($84.1 million net of tax) primarily composed of integration-related activities, are included in gross profit for the nine months ended September 30, 2014 and 2013, respectively.


Costs of $157.7 million ($99.2 million net of tax) and $130.8 million ($80.5 million net of tax) primarily composed of professional fees, integration-related activities and severance costs, including stock compensation, are included in selling, general and administrative expense for the three months ended September 30, 2014 and 2013, respectively.  Costs of $412.8 million ($257.2 million net of tax) and $349.7 million ($213.3 million net of tax) primarily composed of professional fees, integration-related activities and severance costs, including stock compensation, are included in selling, general and administrative expense for the nine months ended September 30, 2014 and 2013, respectively.


The Company recorded a net benefit of $3.5 million ($2.1 million net of tax) within selling, general and administrative expenses for the nine months ended September 30, 2013 in conjunction with a final settlement related to the strategic decision to exit various businesses. 


(5)Debt redemption costs, which includes write-off of deferred financing fees incurred for the early redemption of senior notes, totaled $71.5 million ($44.6 million net of tax) and included in interest expense for the three months ended September 30, 2014.  Debt redemption costs, which includes write-off of deferred financing fees incurred for the early redemption of senior notes, totaled $75.9 million ($47.3 million net of tax) and $68.5 million ($41.6 million net of tax) is included in interest expense for the nine months ended September 30, 2014 and 2013, respectively.


(6) Provision for income taxes includes discrete tax benefits for continuing operations of $83.6 million and $45.6 million for the three and nine months ended September 30, 2014 primarily attributable to a change in estimate resulting in the recognition of tax benefits for a permanent deduction related to our domestic production activities, offset by charges related to interest on and changes in our unrecognized tax benefits and deferred tax implications of newly enacted state laws.  Provision for income taxes includes discrete tax charges for continuing operations of $38.7 million and $29.7 million for the three and nine months ended September 30, 2013 primarily attributable to changes  in unrecognized tax benefits, the deferred tax implications of newly enacted state laws, and the deferred tax implications related to investments in certain foreign subsidiaries for which the Company expects to realize in the foreseeable future. 


(7)Interest income includes a contractual interest payment received from a client of $24.9 million ($15.2 million net of tax) for the three months and nine months ended September 30, 2013. 

SOURCE Express Scripts Holding Company

Cathy Smith, Chief Financial Officer, or Chris McGinnis, Vice President, Investor Relations, (314) 810-3115, investor.relations@express-scripts.com

Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS | E-mail Alerts Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet